Status of the BNCT Project at the HFR Petten

  • R. L. Moss

Abstract

Since 1987, the development of boron neutron capture therapy has been actively pursued at the Petten research site1, where the High Flux Reactor (HFR), a multi-purpose research reactor, has been the focal point of the European Collaboration group’s prime goal, namely: demonstration of BNCT in Europe2. The group has two goals: i) the initiation of clinical trials of glioma patients at the earliest possible date at the HFR, and ii) the creation of conditions for the treatment of other tumours at other centres in Europe. It was decided at an early stage that, amongst other reasons, due to the fact that the tissue at greatest risk is the healthy brain and from the experience gained in Japan, the treatment of glioma by BNCT should be performed with the boron carrier, borocaptate sodium, ie. BSH.

Keywords

Boron Neutron Capture Therapy Phantom Measurement Emergency Exit Reactor Building High Flux Reactor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    R.L.Moss, F.Stecher-Rasmussen, R.Huiskamp, L.Dewit and B.Mijnheer, “The Petten BNCT project”, in: “Progress in Neutron Capture Therapy for Cancer”, Ed. B.J.Allen et al, Plenum Press, Proc. Fourth Int. Symposium Neutron Capture Therapy for Cancer, Sydney, 1990.Google Scholar
  2. 2.
    D.Gabel, “Approach to boron neutron capture therapy in Europe: Goals of a European collaboration on boron neutron capture therapy”, Proc. 2nd. Eur. Particle Accelerator Conf., Nice, 1990Google Scholar
  3. 3.
    R.L.Moss, F.Stecher-Rasmussen, K.Ravensberg, G.Constantine, and P.R.D.Watkins, “Design, construction and installation of an epithermal neutron beam for BNCT at the high flux reactor Petten”, in: “Progress in Neutron Capture Therapy for Cancer”, Ed. B.J.Allen et al, Plenum Press, Proc. Fourth Int. Symposium Neutron Capture Therapy for Cancer, Sydney, 1990.Google Scholar
  4. 4.
    R.L.Moss, “Review of reactor-based neutron beam development for BNCT applications”, in: “Advances in Neutron Capture Therapy”, Ed. A.H.Soloway, R.F.Barth and D.E.Carpenter, Plenum Press, Proc. Fifth Int. Symposium Neutron Capture Therapy for Cancer, Ohio, 1992.Google Scholar
  5. 5.
    P.R.D.Watkins et al, “Nuclear characterisation of the HFR Petten BNCT facility”, idem.Google Scholar
  6. 6.
    J.Crawford, S.Teichmann and F.Stecher-Rasmussen, “A direct comparison of neutron energy spectra at high and low rates”, these proceedings.Google Scholar
  7. 7.
    M.G.Carolan et al, “Validation of Monte Carlo dose planning calculations by epithermal beam dose distribution measurements in phantoms”, these proceedings.Google Scholar
  8. 8.
    C.P.J.Raaijmakers, M.W.Konijnenberg and B.J.Mijnheer, “Clinical dosimetry in an epithermal neutron beam”, these proceedings.Google Scholar
  9. 9.
    R.L.Moss, A.Siefert, P.R.D.Watkins, G.Constantine, F.Stecher-Rasmussen and K.Philipp, “Dosimetric Characterisation, Treatment Planning and Canine Tissue Tolerance Studies at the Petten BNCT Facility”, in: Topics in Dosimetry and Treatment Planning for Neutron Capture Therâpy“, Advanced Medical Publishing, 1994.Google Scholar
  10. 10.
    R.Huiskamp, A.C.Begg, V.G.A.Gregoire, R.Verrijk, D.Gabel, A.Siefert and R.L.Moss, “Radiobiology Studies at Petten: Status on cell culture, mice and dog experiments”, in: “Progress in Neutron Capture Therapy for Cancer”, Ed. B.J.Allen et al, Plenum Press, Proc. Fourth Int. Symposium Neutron Capture Therapy for Cancer, Sydney, 1990.Google Scholar
  11. 11.
    K.Philipp, R.Huiskamp, H.Philippo, J.Casado and R.L.Moss, “Normal tissue tolerance in a large animal model of boron neutron capture irradiation with borocaptate sodium (BSH)”, these proceedings.Google Scholar
  12. 12.
    F.J.Wheeler and D.W.Nigg, “Three-dimensional radiation dose distribution analysis for boron neutron capture therapy”, Nucl.Sci.Eng., 1992: 110: 16–31.Google Scholar
  13. 13.
    D.Haritz, B.Oterson, F.Grochulla, M.Bergmann, R.Huiskamp, D.Preusse and D.Gabel, “Pharmacokinetics and biodistribution in patients with malignant glioma and administration of N-acetylcysteine (N-AC) prior to Borocaptate Sodium (BSH), these proceedings.Google Scholar
  14. 14.
    G.Stragliotto and H.Fankhauser, “Biodistribution and pharmacokinetics of boron-sulfhydryl for boron neutron capture therapy in patients with intercranial tumors.”, Neurosurgery, 1995, 36: 285–293PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • R. L. Moss
    • 1
  1. 1.HFR Unit Joint Research CentreEuropean CommissionPettenThe Netherlands

Personalised recommendations